✦ LIBER ✦

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors

✍ Scribed by Weide, Rudolf; Feiten, Stefan; Friesenhahn, Vera; Heymanns, Jochen; Kleboth, Kristina; Thomalla, Jörg; van Roye, Christoph; Köppler, Hubert

Book ID: 127283595
Publisher: Springer
Year: 2014
Tongue: English
Weight: 401 KB
Volume: 3
Category: Article
ISSN: 2193-1801
DOI: 10.1186/2193-1801-3-535

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anastrozole Plus Trastuzumab Prolongs Pr

Anastrozole Plus Trastuzumab Prolongs Progression-Free Survival in Postmenopausal Patients with HER2-Positive and Hormone Receptor–Positive Metastatic Breast Cancer: A Review of the TAnDEM Study

✍ Basi, Sanraj K.; Mackey, John R. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Tumor hormone/HER2 receptor status and p

Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe

✍ Gao, Sue; Barber, Beth; Schabert, Vernon; Ferrufino, Cheryl 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 267 KB

How relevant is hormone receptor status

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?

✍ Nadine Norton, Edith A Perez 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 91 KB

Quality-adjusted survival analysis of fi

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib

✍ Sherrill, Beth; Sherif, Bintu; Amonkar, Mayur M.; Maltzman, Julie; O’Rourke, Lis 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 497 KB

AKT2 is frequently upregulated in HER-2/

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival

✍ Bacus, Sarah S; Altomare, Deborah A; Lyass, Ljuba; Chin, Dot Mon; Farrell, Micha 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 425 KB

Hormonal Receptor Positive, HER2 Negativ

Hormonal Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC HR+HER2-): Pre and Post-Progression Costs Under the Public Health Care System (SUS) and Societal Perspectives in Brazil

✍ Haas, L.C.; Fernandes, R.A.; Bines, J.; Caldas, A.; Valentim, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB